POZEN Inc., a pharmaceutical company, develops products for the treatment of acute and chronic pain, and pain related conditions in the United States and internationally. Its principal PA product candidates comprise PA32540 and PA8140 for secondary prevention of cardiovascular and cerebrovascular disease in patients at risk for gastric ulcers, which have completed clinical development in the United States. The company s products also include VIMOVO for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as to decrease the risk of developing gastric ulcers in patients at risk of developing non-steroidal anti-inflammatory drugs (NSAID)-associated gastric ulcers. It has collaborations with GlaxoSmithKline for the development and commercialization of proprietary combinations of a triptan and a long-acting NSAID; and sanofi-aventis U.S. LLC for the commercialization of PA product candidates, as well as with AstraZeneca AB. The company was founded in 1996 and is headquartered in Chapel Hill, North Carolina.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• No BuyIns.Net Alerts Available for POZN